期刊文献+

药源性疾病与合理用药 被引量:8

Drug-induced Disease and Rational Medication
下载PDF
导出
摘要 目的:探讨药源性疾病的分类、诊断、处理及预防。方法:通过文献查阅和总结.对药源性疾病的分类、诊断、处理及预防分别进行阐述。结果:药源性疾病的发生与多种因素有关,不合理用药是其主要诱因之一。结论:药师和医生应重视不合理用药可能带来的后果,关注药物的合理使用问题.以减少药源性疾病的发生。 Objective: To discuss the typing, diagnosis, treatment and prevention of drug-induced disease. Methods: Describe the typing, diagnosis, treatment and prevention of drug-induced disease respectively through literature searching and summarizing. Results: Most drug-induced disease is closely related to irrational medication. Conclusion: Pharmacists and doctors should put emphasis on the drug-induced disease, strengthen rational medication, and lessen the incidence rate of drug-induced disease.
出处 《药品评价》 CAS 2010年第8期34-37,共4页 Drug Evaluation
关键词 药源性疾病 诊断 预防 合理用药 Drug-induced disease Diagnosis Prevention Rational medication
  • 相关文献

参考文献4

二级参考文献11

  • 1郑荣远,王小同,金得辛,张旭,章锦湘,林正章.左旋咪唑引起脑炎综合征[J]中国神经精神疾病杂志,1988(04).
  • 2Randerson J.More than half of US drug safety studies never see the light of day[OL]. http://www.guardian.co.uk/science/2008/sep/23/clinical.trials . 2009
  • 3Steven Galson.CDER facts and figures[OL]. http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/WhatWeDo/UCM122356. pdf . 2009
  • 4Buck ML,Gurka MJ,Goodkin HP.Postmarketing modifications in the safety labeling of the new antiepileptics. Neurology . 2007
  • 5Perez-Miranda J,Aguirre J,Parrilla JL, etal.Felbamate:perspectives for new antiepileptic treatment. Revue Neurologique . 1995
  • 6Mackey A,Brinker C,A Beitz JG.Alosetron Postmarketing Experience. 2003 FDA Science Forum .
  • 7The Cardiac Arrhythmia Suppression Trial Investigators.Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The New England Journal of Medicine . 1989
  • 8Echt DS,Liebson PR,Mitchell LB,et al.Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. New England Journal of Medicine, The . 1991
  • 9Writing Group for the Women’s Health Initiative Investigators.Risks and benefits of estrogen plus progestin in healthy postmenopausal women-Principal results from the Women’s Health Initiative randomized controlled trial. Journal of the American Medical Association, The . 2002
  • 10ANDRESEN V,,HOLLERBACH S.Reassessing the benefits and risks of alosetron:what is its place in the treatment of irritable bowel syndrome?. Drug Safety . 2004

共引文献45

同被引文献73

引证文献8

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部